YBX1 and lung carcinoma: While there is strong evidence supporting YB-1-driven resistance to platinum chemotherapy in other cancers, a study looking at the effect of YB-1 knockdown on cisplatin or other platinum drug sensitivity in lung cancer or MPM cells is still required.